Mymetics Corp (MYMX)

[Phosphene]

"It should be noted that the challenge route was intravaginal – quite different from all other preclinical AIDS vaccine development studies that mostly used the intrarectal challenge route."

The current HIV virosomal vaccine MYM-V201 that has no added adjuvant can elicit a front-line mucosal defenses that could prevent male-to-female HIV transmission.

MIT, Dartmouth, Bern, Freddy Hutch and The Duke boys will get this fast tracked.

Funding
This work was supported by the Bill & Melinda Gates Foundation Grant OPP1111654 to RMR, NIH U19 AI142636 to RMR and SF, Collaboration for AIDS Vaccine Discovery, Vaccine Immune Monitoring Center (CAVIMC) grant OPP1146996, the National Institutes of Health/Office of Research Infrastructure Programs (NIH/ORIP) Grant P51 OD011133 to the Southwest National Primate Research Center (SNPRC) in San Antonio, TX, and National Institute of Allergy and Infectious Diseases (NIAID, Duke Center for AIDS Research (CFAR) grant P30 AI064518.